Dergiler / Eurasian Journal of Medical Investigation / 2021 / Cilt: 5 - Sayı: 1

Prognostic Significance of Microsatellite Instability in Turkish Patients with Stage II and III Colorectal Cancer

Sayfa
62–66
Yayın Tarihi
2022-10-12
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

However, the MSI status did not have a significant impact on survival outcomes.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objectives: Microsatellite instability (MSI) – a form of pervasive erratic expansion of microsatellites – can be identifiedin 15−20% of all patients with sporadic colorectal cancer (CRC).
📊
Temel Bulgular & Veri:We specifically focused on patients with stage 2and stage 3 CRC because they are a heterogeneous group in need of an improved clinical management.Methods: A total of 81 patients were enrolled into the study.
💡
Sonuç & Katkı:However, the MSI status did not have a significant impact on survival outcomes.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Objectives: Microsatellite instability (MSI) – a form of pervasive erratic expansion of microsatellites – can be identifiedin 15−20% of all patients with sporadic colorectal cancer (CRC). To gain further insight into the prognostic value of MSIin CRC, we sought to investigate this issue in a nonselected sample of Turkish patients seen in daily practice and toestablish whether the MSI status is associated with survival outcomes. We specifically focused on patients with stage 2and stage 3 CRC because they are a heterogeneous group in need of an improved clinical management.Methods: A total of 81 patients were enrolled into the study. MSI analysis was performed a dedicated platform andclassified into three types, as follows: microsatellite stability (MSS), low microsatellite instability (MSI-L), and high microsatellite instability (MSI-H). Disease-free survival (DFS) and overall survival (OS) served as the main outcome measures.Results: Patients with MSI-H had a significantly higher frequency of right colon tumors compared with those withMSI-L/MSS. Moreover, no cases of rectal tumor were observed in the former group (p=0.002). As a result, the use ofradiotherapy was limited to patients with MSI-L/MSS (p=0.02). Patients with MSI-H did not differ from those with MSI-L/MSS both in terms of DFS and OS.Conclusion: Our study demonstrates that Turkish patients with proximal colon cancer more frequently have MSI-Hcompared to those with distal colon cancer. However, the MSI status did not have a significant impact on survival outcomes.

🔖

Bu Makaleye Atıf Yap

SAĞ, Ş. Ö., IŞIK, Ö., ÇUBUKÇU, E., OCAK, B., HAFIZOĞLU, M., ŞAHİN, A. B., DELİGÖNÜL, A., ORHAN, S. O., AVCI, N., KURT, M., HAFIZOĞLU, E. (2022). Prognostic Significance of Microsatellite Instability in Turkish Patients with Stage II and III Colorectal Cancer. Eurasian Journal of Medical Investigation, Cilt: 5 - Sayı: 1, 62–66. https://ajindex.com/articles/508602

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Prz Gastroenterol 2019;14:89–103
  2. Keum N, Giovannucci E. Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. Nat Rev Gastroenterol Hepatol 2019;16:713–32
  3. Mármol I, Sánchez-de-Diego C, Pradilla Dieste A, Cerrada E, Rodriguez Yoldi MJ. Colorectal carcinoma: a general overview and future perspectives in colorectal cancer. Int J Mol Sci 2017;18:197
  4. Costas-Chavarri A, Nandakumar G, Temin S, Lopes G, Cervantes A, Cruz C, et al. Treatment of Patients With Early-Stage Colorectal Cancer: ASCO Resource-Stratified Guideline. J Glob Oncol 2019;5:1–19
  5. Upadhyay S, Dahal S, Bhatt VR, Khanal N, Silberstein PT. Chemotherapy use in stage III colon cancer: a National Cancer Database analysis. Ther Adv Med Oncol 2015;7:244–51
  6. Kannarkatt J, Joseph J, Kurniali PC Al-Janadi A, Hrinczenko B. Adjuvant chemotherapy for stage II colon cancer: a clinical dilemma. J Oncol Pract 2017;13:233–41
  7. Giannakis M, Ng K. To treat or not to treat: adjuvant therapy for stage II colon cancer in the era of precision oncology. J Oncol Pract 2017;13:242–4. 8. van Eeghen EE, Bakker SD, van Bochove A, Loffeld RJ. High risk stage 2 and stage 3 colon cancer, predictors of recurrence and effect of adjuvant therapy in a nonselected population. Int Sch Res Notices 2015:790186
  8. Dienstmann R, Mason MJ, Sinicrope FA, Phipps AI, Tejpar S, Nesbakken A, et al. Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study. Ann Oncol 2017;28:1023–31
  9. Yamamoto H, Imai K. Microsatellite instability: an update. Arch Toxicol 2015;89:899–921
  10. De' Angelis GL, Bottarelli L, Azzoni C, De' Angelis N, Leandro G, Di Mario F, et al. Microsatellite instability in colorectal cancer. Acta Biomed 2018;89:97–101
  11. Battaglin F, Naseem M, Lenz HJ, Salem ME. Microsatellite instability in colorectal cancer: overview of its clinical significance and novel perspectives. Clin Adv Hematol Oncol 2018;16:735– 45
  12. Kawakami H, Zaanan A, Sinicrope FA. Microsatellite instability testing and its role in the management of colorectal cancer. Curr Treat Options Oncol 2015;16:30
  13. Babaei H, Zeinalian M, Emami MH, Hashemzadeh M, Farahani N, Salehi R. Simplified microsatellite instability detection protocol provides equivalent sensitivity to robust detection strategies in Lynch syndrome patie